Home  »  Companies   »  ProKidney Corp (NASDAQ: PROK) Shares Rose Recently...

ProKidney Corp (NASDAQ: PROK) Shares Rose Recently. However, Trouble May Still Be Lurking.

ProKidney Corp (NASDAQ:PROK) price closed higher on Monday, November 20, jumping 45.45% above its previous close.

A look at the daily price movement shows that the last close reads $1.21, with intraday deals fluctuated between $1.27 and $1.83. The company’s 5Y monthly beta was ticking 1.23. Taking into account the 52-week price action we note that the stock hit a 52-week high of $14.19 and 52-week low of $1.12. The stock subtracted -0.56% on its value in the past month.

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


ProKidney Corp, which has a market valuation of $108.40 million, is expected to release its quarterly earnings report Nov 14, 2023. Analysts tracking PROK have forecast the quarterly EPS to shrink by -0.16 per share this quarter, while the same analysts predict the annual EPS to hit -$0.64 for the year 2023 and up to -$0.69 for 2024. In this case, analysts estimate an annual EPS growth of -178.30% for the year and -7.80% for the next year.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with 1 upward and no downward reviews. On the technical perspective front, indicators give PROK a short term outlook of 50% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 100% Sell.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 6 analysts have assigned PROK a recommendation rating as follows: 2 rate it as a Hold; 4 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the ProKidney Corp (PROK) stock as Underweight, with 0 recommending Sell. In general, analysts have rated the stock Overweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

The overview shows that PROK’s price is at present 9.30% off the SMA20 and -47.84% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 41.30, with weekly volatility standing at 29.41%. The indicator jumps to 17.54% when calculated based on the past 30 days. ProKidney Corp (NASDAQ:PROK)’s beta value is holding at 0.95, while the average true range (ATR) indicator is currently reading 0.32. Considering analysts have assigned the stock a price target range of $6.00-$15.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $9.60. Based on this estimate, we see that current price is roughly -240.91% off the estimated low and -752.27% off the forecast high. Investors will no doubt be excited to see the share price fall to $8.00, which is the median consensus price, and at that level PROK would be -354.55% from current price.

An analysis of the ProKidney Corp (NASDAQ:PROK) stock in terms of its daily trading volume indicates that the 3-month average is 750.61K. However, this figure increases on the past 10-day timeline to an average of 0.98 million.

Current records show that the company has 61.54M in outstanding shares. The insiders’ percentage holdings are 42.53% of outstanding shares while the percentage share held by institutions stands at 54.34%. The stats also highlight that short interest as of Oct 30, 2023, stood at 9.87 million shares, which puts the short ratio at the time at 10.4. From this we can glean that short interest is 14.73% of company’s current outstanding shares. Notably, we see that shares short in October rose slightly given the previous month’s figure stood at 8.1 million. But the -74.34% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.